Quality of life after hepatitis B treatment outcomes
Part of Digestive system, Infections clinical trials.
This study looks at how different outcomes of chronic hepatitis B treatment affect patients' quality of life. It includes people who have been functionally cured, those still on treatment, those who relapsed, and healthy controls to compare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have participated in the 'Zhufeng Project' and your clinical data is available.
- You fit into one of these groups: functionally cured (treatment stopped, HBsAg negative for at least 6 months), on long-term antiviral treatment (at least 1 year, with stable virus suppression), had a relapse after stopping treatment, or you are a healthy volunteer without hepatitis B.
- Your liver enzyme (ALT) level is within normal range for your group.
- You do not have serious liver disease (like cirrhosis or liver cancer), other cancers, or co-infections with HIV, HCV, or HDV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This study looks at how doctors decide which patients to prioritize for hepatitis B cure, and how cost-effective these treatments are. If you have been cured of hepatitis B, your information can help improve care for others.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.